<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Bras Cir Cardiovasc</journal-id><journal-title-group><journal-title>Revista Brasileira de Cirurgia Cardiovascular : &#x000f3;rg&#x000e3;o oficial da Sociedade Brasileira de Cirurgia Cardiovascular</journal-title></journal-title-group><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25859862</article-id><article-id pub-id-type="pmc">4389529</article-id><article-id pub-id-type="doi">10.5935/1678-9741.20140055</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Determinants of peak VO<sub>2</sub> in heart transplant
recipients</article-title><trans-title-group xml:lang="pt"><trans-title>Determinantes do pico de VO<sub>2</sub> em transplantados
card&#x000ed;acos</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Carvalho</surname><given-names>Vitor Oliveira</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff01">1</xref><xref ref-type="corresp" rid="c01"/></contrib><contrib contrib-type="author"><name><surname>Guimar&#x000e3;es</surname><given-names>Guilherme Veiga</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Campos-Vieira</surname><given-names>Marcelo Luiz</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Catai</surname><given-names>Aparecida Maria</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Oliveira-Carvalho</surname><given-names>Vagner</given-names></name><degrees>MsC</degrees><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Ayub-Ferreira</surname><given-names>Silvia Moreira</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Bocchi</surname><given-names>Edimar Alcides</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff01">1</xref></contrib></contrib-group><aff id="aff01"><label>1</label>Instituto do Cora&#x000e7;&#x000e3;o do Hospital das Cl&#x000ed;nicas
da Faculdade de Medicina da USP (InCor HC-FMUSP), S&#x000e3;o Paulo, Brazil</aff><author-notes><corresp id="c01">Correspondence address: Vitor Oliveira Carvalho, Universidade
Federal de Sergipe (UFS), Departamento de Fisioterapia/Hospital
Universit&#x000e1;rio, Rua Cl&#x000e1;udio Batista , sn, Aracaju, SE, Brazil - Zip
code: 49060-000. E-mail <email>vitor.ufs@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2015</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2015</year></pub-date><volume>30</volume><issue>1</issue><fpage>9</fpage><lpage>15</lpage><history><date date-type="received"><day>03</day><month>12</month><year>2013</year></date><date date-type="accepted"><day>24</day><month>2</month><year>2014</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License which permits
unrestricted non-commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To establish the determinants of the peak VO<sub>2</sub> in heart transplant
recipients.</p></sec><sec><title>Methods</title><p>Patient's assessment was performed in two consecutive days. In the first day,
patients performed the heart rate variability assessment followed by a
cardiopulmonary exercise test. In the second day, patients performed a
resting echocardiography. Heart transplant recipients were eligible if they
were in a stable condition and without any evidence of tissue rejection
diagnosed by endomyocardial biopsy. Patients with pacemaker,
noncardiovascular functional limitations such as osteoarthritis and chronic
obstructive pulmonary disease were excluded from this study.</p></sec><sec><title>Results</title><p>Sixty patients (68% male, 48 years and 64 months following heart
transplantation) were assessed. Multivariate analysis selected the following
variables: receptor's gender (<italic>P</italic> =0.001), receptor age
(<italic>P</italic> =0.049), receptor Body Mass Index
(<italic>P</italic> =0.005), heart rate reserve (<italic>P</italic>
&#x0003c;0.0001), left atrium diameter (<italic>P</italic> =0.016). Multivariate
analysis showed r=0.77 and r2=0.6 with <italic>P</italic> &#x0003c;0.001.
Equation: peakVO<sub>2</sub> =32.851 - 3.708 (receptor gender) - 0.067
(receptor age) - 0.318 (receptor BMI) + 0.145 (heart rate reserve) - 0.111
(left atrium diameter).</p></sec><sec><title>Conclusion</title><p>The determinants of the peak VO<sub>2</sub> in heart transplant recipients
were: receptor sex, age, Body Mass Index, heart rate reserve and left atrium
diameter. Heart rate reserve was the unique variable positively associated
with peak VO<sub>2</sub> . This data suggest the importance of the
sympathetic reinnervation in peak VO<sub>2</sub> in heart transplant
recipients.</p></sec></abstract><trans-abstract xml:lang="pt"><sec><title>Objetivo</title><p>Estabelecer os determinantes do VO<sub>2</sub> pico em transplantados de
cora&#x000e7;&#x000e3;o.</p></sec><sec><title>M&#x000e9;todos</title><p>Avalia&#x000e7;&#x000e3;o do paciente foi realizada em dois dias consecutivos.
No primeiro dia, os pacientes realizaram a avalia&#x000e7;&#x000e3;o da
variabilidade da frequ&#x000ea;ncia card&#x000ed;aca seguida de um teste de
esfor&#x000e7;o cardiopulmonar. No segundo dia, os pacientes realizaram
ecocardiografia de repouso. Os transplantados foram eleg&#x000ed;veis se
estivessem em uma condi&#x000e7;&#x000e3;o est&#x000e1;vel e sem qualquer
evid&#x000ea;ncia de rejei&#x000e7;&#x000e3;o diagnosticada por bi&#x000f3;psia
endomioc&#x000e1;rdica. Pacientes com marca-passo, limita&#x000e7;&#x000f5;es
funcionais n&#x000e3;o cardiovasculares, tais como osteoartrite e
doen&#x000e7;a pulmonar obstrutiva cr&#x000f4;nica foram exclu&#x000ed;dos
deste estudo.</p></sec><sec><title>Resultados</title><p>Sessenta pacientes (68% do sexo masculino, 48 anos e 64 meses ap&#x000f3;s o
transplante card&#x000ed;aco) foram avaliados. A an&#x000e1;lise multivariada
selecionou as seguintes vari&#x000e1;veis: sexo (<italic>P</italic> =0,001),
idade (<italic>P</italic> =0,049), &#x000cd;ndice de Massa Corporal
(<italic>P</italic> =0,005), frequ&#x000ea;ncia card&#x000ed;aca de
reserva (<italic>P</italic> &#x0003c;0,0001), di&#x000e2;metro do &#x000e1;trio
esquerdo (<italic>P</italic> =0,016), vari&#x000e1;veis do receptor. A
an&#x000e1;lise multivariada mostrou r=0,77 e r2=0,6, com <italic>P</italic>
&#x0003c;0,001. Equa&#x000e7;&#x000e3;o: VO<sub>2</sub> =32,851 - 3,708 (sexo
receptor) - 0,067 (idade receptor) - 0,318 (IMC receptor) + 0,145
(frequ&#x000ea;ncia card&#x000ed;aca de reserva) - 0,111 (di&#x000e2;metro de
&#x000e1;trio esquerdo).</p></sec><sec><title>Conclus&#x000e3;o</title><p> Os determinantes do pico de VO<sub>2</sub> em transplantados de
cora&#x000e7;&#x000e3;o foram: sexo receptor, idade, &#x000cd;ndice de Massa
Corporal, frequ&#x000ea;ncia card&#x000ed;aca de reserva e di&#x000e2;metro do
&#x000e1;trio esquerdo. A frequ&#x000ea;ncia card&#x000ed;aca de reserva foi a
&#x000fa;nica vari&#x000e1;vel positivamente associada com o pico de
VO<sub>2</sub> . Estes dados sugerem a import&#x000e2;ncia da
reinerva&#x000e7;&#x000e3;o simp&#x000e1;tica no pico de VO<sub>2</sub> em
transplantados de cora&#x000e7;&#x000e3;o.</p></sec></trans-abstract><kwd-group><kwd>Heart Transplantation</kwd><kwd>Exercise</kwd><kwd>Exercise Tolerance</kwd></kwd-group><funding-group><award-group><funding-source>FAPESP (Funda&#x000e7;&#x000e3;o de Amparo a Pesquisa do Estado de
S&#x000e3;o Paulo)</funding-source><award-id>07137-3</award-id></award-group></funding-group></article-meta></front><body><table-wrap id="t02" orientation="portrait" position="float"><table frame="box" rules="groups"><thead><tr><th colspan="2" align="left" rowspan="1">Abbreviations, acronyms &#x00026;&#x000a0;symbols</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">BMI</td><td align="left" rowspan="1" colspan="1">Body mass index</td></tr><tr><td align="left" rowspan="1" colspan="1">BNP</td><td align="left" rowspan="1" colspan="1">B-type Natriuretic Peptide</td></tr><tr><td align="left" rowspan="1" colspan="1">DT</td><td align="left" rowspan="1" colspan="1">Deceleration time</td></tr><tr><td align="left" rowspan="1" colspan="1">ECA</td><td align="left" rowspan="1" colspan="1">Angiotensin conversor enzyme inhibitors</td></tr><tr><td align="left" rowspan="1" colspan="1">IVRT</td><td align="left" rowspan="1" colspan="1">Isovolumic relaxation time</td></tr><tr><td align="left" rowspan="1" colspan="1">LF/HF</td><td align="left" rowspan="1" colspan="1">Low/high frequency domain in heart rate variability</td></tr><tr><td align="left" rowspan="1" colspan="1">RRi</td><td align="left" rowspan="1" colspan="1">R-R intervals</td></tr><tr><td align="left" rowspan="1" colspan="1">VO<sub>2</sub>
</td><td align="left" rowspan="1" colspan="1">Oxygen consumption</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Heart transplantation is a worldwide procedure indicated to patients with refractory
heart failure. It is well known that heart transplant improves patient's survival,
quality of life and exercise capacity, when compared to pre-transplant
condition<sup> [<xref rid="r01" ref-type="bibr">1</xref> ,<xref rid="r02" ref-type="bibr">2</xref> ]</sup> .</p><p>Although heart transplant recipients have an exercise capacity greater than before
the procedure, it is known that the physical capacity restoration to normal levels
does not always occur<sup> [<xref rid="r01" ref-type="bibr">1</xref> ,<xref rid="r02" ref-type="bibr">2</xref> ]</sup> . This is attributed to
physical deconditioning resulting from previous heart failure<sup> [<xref rid="r03" ref-type="bibr">3</xref> ]</sup> , a low chronotropic
response (as a result of a cardiac denervation, also accessed by heart rate
variability)<sup> [<xref rid="r04" ref-type="bibr">4</xref>
]</sup> and, in many cases, impairment in cardiac function after
transplantation<sup> [<xref rid="r02" ref-type="bibr">2</xref>
]</sup> . The cardiac systolic function of the transplanted heart seems
to be normal in most patients, while diastolic dysfunction appears to be present in
most of the transplanted heart. Diastolic dysfunction was recently identified as one
of the factors that seem to influence negatively the maximal and submaximal exercise
capacity in heart transplant recipients<sup> [<xref rid="r05" ref-type="bibr">5</xref> ,<xref rid="r06" ref-type="bibr">6</xref> ]</sup> . Despite
this, little is known about the determinants of exercise capacity in heart
transplant recipients.</p><p>The aim of this study was to establish the determinants of the peak VO<sub>2</sub> in
heart transplant recipients.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Study design</title><p>This study was performed in a tertiary cardiology hospital in Brazil. Patient's
assessment was performed in two consecutive days. In the first day, patients
performed the heart rate variability assessment followed by a cardiopulmonary
exercise test. In the second day, patients performed a resting
echocardiography.</p></sec><sec><title>Study population</title><p>Heart transplant recipients were eligible if they were in a stable condition
(for, at least, 3 months) and without any evidence of tissue rejection diagnosed
by endomyocardial biopsy. Patients with pacemaker, noncardiovascular functional
limitations such as osteoarthritis and chronic obstructive pulmonary disease
were excluded from this study. Patients were recruited from a tertiary
cardiology hospital from September 2010 to November 2011. Subjects'
characteristics are listed in <xref ref-type="table" rid="t01">Table 1</xref>
.</p><table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><p>Characterization of study participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Number of patients (%), dose(mg/day)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Etiology:</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Chagas (%)</td><td align="center" rowspan="1" colspan="1">45%</td></tr><tr><td align="left" rowspan="1" colspan="1">Non-Chagas (%)</td><td align="center" rowspan="1" colspan="1">55%</td></tr><tr><td align="left" rowspan="1" colspan="1">Men (%)</td><td align="center" rowspan="1" colspan="1">68%</td></tr><tr><td align="left" rowspan="1" colspan="1">Recipients age (years)</td><td align="center" rowspan="1" colspan="1">48&#x000b1;15</td></tr><tr><td align="left" rowspan="1" colspan="1">Donors age (years)</td><td align="center" rowspan="1" colspan="1">31&#x000b1;11</td></tr><tr><td align="left" rowspan="1" colspan="1">Donors weight (kg)</td><td align="center" rowspan="1" colspan="1">76&#x000b1;9</td></tr><tr><td align="left" rowspan="1" colspan="1">Recipients weight (kg)</td><td align="center" rowspan="1" colspan="1">68&#x000b1;13</td></tr><tr><td align="left" rowspan="1" colspan="1">Donors height (cm)</td><td align="center" rowspan="1" colspan="1">176&#x000b1;7</td></tr><tr><td align="left" rowspan="1" colspan="1">Recipients height (cm)</td><td align="center" rowspan="1" colspan="1">166&#x000b1;10</td></tr><tr><td align="left" rowspan="1" colspan="1">Ischemic time (min)</td><td align="center" rowspan="1" colspan="1">206&#x000b1;115</td></tr><tr><td align="left" rowspan="1" colspan="1">Recipients BMI (Kg/m<sup>2</sup> )</td><td align="center" rowspan="1" colspan="1">25&#x000b1;4</td></tr><tr><td align="left" rowspan="1" colspan="1">Donors BMI (Kg/m<sup>2</sup> )</td><td align="center" rowspan="1" colspan="1">25&#x000b1;2</td></tr><tr><td align="left" rowspan="1" colspan="1">Time following heart transplant (months)</td><td align="center" rowspan="1" colspan="1">64&#x000b1;54</td></tr><tr><td align="left" rowspan="1" colspan="1">Resting heart rate (bpm)</td><td align="center" rowspan="1" colspan="1">82&#x000b1;12</td></tr><tr><td align="left" rowspan="1" colspan="1">Recipients heart rate reserve (bpm)</td><td align="center" rowspan="1" colspan="1">49&#x000b1;17</td></tr><tr><td align="left" rowspan="1" colspan="1"> % of age-predicted peak heart rate</td><td align="center" rowspan="1" colspan="1">77&#x000b1;12</td></tr><tr><td align="left" rowspan="1" colspan="1"> % of heart rate drop in the second minute of
recovery</td><td align="center" rowspan="1" colspan="1">8&#x000b1;8</td></tr><tr><td align="left" rowspan="1" colspan="1">Left atrium diameter</td><td align="center" rowspan="1" colspan="1">44&#x000b1;10</td></tr><tr><td align="left" rowspan="1" colspan="1">Cold ischemia time (min)</td><td align="center" rowspan="1" colspan="1">207&#x000b1;115</td></tr><tr><td align="left" rowspan="1" colspan="1">VE/VCO<sub>2</sub> slope</td><td align="center" rowspan="1" colspan="1">30&#x000b1;6</td></tr><tr><td align="left" rowspan="1" colspan="1">Right ventricle diameter (mm)</td><td align="center" rowspan="1" colspan="1">22&#x000b1;3</td></tr><tr><td align="left" rowspan="1" colspan="1">Left ventricle diastolic diameter (mm)</td><td align="center" rowspan="1" colspan="1">48&#x000b1;4</td></tr><tr><td align="left" rowspan="1" colspan="1">Left ventricle ejection fraction (%)</td><td align="center" rowspan="1" colspan="1">62&#x000b1;5</td></tr><tr><td align="left" rowspan="1" colspan="1">E/E&#x02019; ratio</td><td align="center" rowspan="1" colspan="1">6.8&#x000b1;2.3</td></tr><tr><td align="left" rowspan="1" colspan="1">LF/HF</td><td align="center" rowspan="1" colspan="1">6.9&#x000b1;8.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Medication:</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Cyclosporine</td><td align="center" rowspan="1" colspan="1">71%, 174&#x000b1;58 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">Diuretics</td><td align="center" rowspan="1" colspan="1">8.3%</td></tr><tr><td align="left" rowspan="1" colspan="1">ACE inhibitors (enalapril)</td><td align="center" rowspan="1" colspan="1">10%, 23&#x000b1;14 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">Angiotensin receptor antagonist (losartan)</td><td align="center" rowspan="1" colspan="1">10%, 62&#x000b1;31 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">Corticosteroids (prednisone)</td><td align="center" rowspan="1" colspan="1">30%, 5.2&#x000b1;3.4 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">Azathioprine</td><td align="center" rowspan="1" colspan="1">30%, 76&#x000b1;25 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">Mycophenolate</td><td align="center" rowspan="1" colspan="1">37%, 1096&#x000b1;422 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">Tacrolimus</td><td align="center" rowspan="1" colspan="1">25%, 7&#x000b1;4 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">Sirolimus</td><td align="center" rowspan="1" colspan="1">1.6%, 1 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">Everolimus</td><td align="center" rowspan="1" colspan="1">3.3%, 1&#x000b1;0.35 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">Calcium channel blocker (diltiazem)</td><td align="center" rowspan="1" colspan="1">58%, 126&#x000b1;71 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">Ezetimibe</td><td align="center" rowspan="1" colspan="1">1.6%, 10 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">Simvastatin</td><td align="center" rowspan="1" colspan="1">68.3%,11.4&#x000b1;4.4 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">Hydralazine</td><td align="center" rowspan="1" colspan="1">6.6%, 144&#x000b1;116 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">Metformin</td><td align="center" rowspan="1" colspan="1">6.6%,1700&#x000b1;00 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">Fluoxetine</td><td align="center" rowspan="1" colspan="1">3.3%, 32&#x000b1;11 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">Gabapentin</td><td align="center" rowspan="1" colspan="1">1.6%, 400 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">Olanzapine</td><td align="center" rowspan="1" colspan="1">5%, 10 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">Topiramate</td><td align="center" rowspan="1" colspan="1">3.3%, 125&#x000b1;106 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">Bromazepam</td><td align="center" rowspan="1" colspan="1">5%, 3 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">Insulin</td><td align="center" rowspan="1" colspan="1">7.5%, 69&#x000b1;53 mg/day</td></tr></tbody></table><table-wrap-foot><fn><p>
<italic>BMI=Body mass index, ECA=Angiotensin conversor enzyme
inhibitors. LF/HF=Low/high frequency domain in heart rate
variability</italic>
</p></fn></table-wrap-foot></table-wrap><p>This protocol was approved by the Ethical Committee of our institution. All
patients provided informed consent prior to participation.</p></sec><sec><title>Variables considered to be potentially associated with peak VO<sub>2</sub>
</title><p>We considered to be potentially associated with peak VO<sub>2</sub> as follows:
donor and recipient age and body mass index (BMI), etiology of heart failure
before transplantation (Chagas and non-Chagas), recipient heart rate reserve,
gender, percentage of age-predicted peak heart rate, percentage of heart rate
drop in the second minute of recovery in the cardiopulmonary test, left atrium
diameter, cold ischemia time, time following heart transplantation, resting
heart rate, VE/VCO<sub>2</sub> slope, right ventricle diameter, left ventricle
diastolic diameter, left ventricle ejection fraction, E/E' ratio and low/high
frequency domain in heart rate variability (LF/HF).</p></sec><sec><title>Cardiopulmonary exercise test</title><p>All patients were asked to refrain from both strenuous physical activity and the
consumption of any stimulants (e.g., coffee, tobacco, alcohol) for 24h prior to
the cardiopulmonary exercise test. Patients' last meal was ingested at least 2h
before the test. Heart transplant recipients underwent the test on a
programmable treadmill (TMX425 Stress Treadmill; TrackMaster, Newton, KS, USA)
in a temperature-controlled room (21-23&#x000ba;C) between 10-12am with a
standard 12-lead continuous ECG monitor (CardioSoft 6.5; GE Medical Systems IT,
Milwaukee, WI, USA). Blood pressure monitoring was performed by an automatic
device. Resting heart rate was considered the 20-min average in a supine
position. Minute ventilation, oxygen uptake, carbon dioxide output and other
cardiopulmonary variables were acquired breath-by-breath by a computerized
system (Vmax Encore29; SensorMedics, Yorba Linda, CA, USA).</p><p>Metabolic data were computed as the mean of the final 30 s of the resting period,
whereas peak of VO<sub>2</sub> and peak heart rate were the mean values of the
final 30 s of effort before exhaustion. The respiratory exchange ratios were
recorded as the averaged samples obtained during each stage of a modified
Naughton protocol. A satisfactory cardiopulmonary exercise test was
characterized by a peak of respiratory exchange ratio&#x0003e;1.05 and symptoms of
maximum effort. Heart rate reserve [bpm] was defined as maximum
heart rate achieved in the cardiopulmonary exercise test - average of 10-min
resting heart rate in the supine position. Heart rate recovery was assessed
during the first and second minutes after cardiopulmonary exercise test.</p></sec><sec><title>Echocardiography</title><p>The assessment followed the recommendations of the American Society of
Ecocardiography<sup> [<xref rid="r07" ref-type="bibr">7</xref>
]</sup> . We used a commercially available equipment, model IE 33,
Philips Medical Systems, Andover, MA, USA. The acquired data considered
bidimensional echocardiography, pulsed Doppler, continuous wave Doppler, tissue
Doppler and color flow mapping. It was obtained at least three measurements of
each echocardiographic variable and the average was considered. We analyzed:
left ventricle diameters and volumes, left ventricle ejection fraction
(Simpson's rule), left ventricle mass index, left ventricle diastolic assessment
(pulsed Doppler of mitral inflow and the study of the flow of pulmonary veins
and Tissue Doppler). Thus, we analyzed with pulsed Doppler, E and A waves, E/A
ratio, deceleration time (DT), isovolumic relaxation time (IVRT), systolic
component of the pulmonary venous flows (S wave), diastolic component of the
pulmonary venous flow (D wave), S/D ratio. The analysis with tissue Doppler was
obtained in apical four and two chambers with sample volume of 1 to 2 mm. It was
checked to the maximum rate of myocardial displacement at the beginning and end
of the diastole (E' and A' wave respectively) and during systole (S' wave) at
the septal ring, side ring, bottom ring, front ring of right ventricle.
Measurement of E/E'ratio was performed in the left ventricular annulus, from the
basal septal and lateral segments (considered mean values).</p></sec><sec><title>Heart rate variability</title><p>Experimental protocol: All the heart transplant recipients remained at rest for
10 minutes on the supine position and were instructed to breathe spontaneously.
Then, instantaneous R-R intervals (RRi) were recorded for 10 min with a digital
telemetry system, consisting of a transmitter placed on the patient's chest and
a HR monitor (Polar&#x000ae; RS800CX; Polar Electro Oy, Kempele, Finland) This
system detects ventricular depolarization, corresponding to the R wave on the
electrocardiogram, at a sampling rate of 500 Hz, which had been previously
validated<sup> [<xref rid="r08" ref-type="bibr">8</xref>
]</sup> . The signals were transmitted to a receiver and then to a
computer for subsequent analysis. Data analysis: The RRi sequence of length
n=256 beats was selected for each subject. The length of greatest stability was
chosen from the central region of the time series. The mean and variance of the
RRi were also calculated. HRV spectral analysis: The HRV frequency domain
analysis was performed with an autoregressive model<sup> [<xref rid="r09" ref-type="bibr">9</xref> ,<xref rid="r10" ref-type="bibr">10</xref> ]</sup> , on previously selected RRi sequences. Two
main spectral components were considered: low frequency (LF - from 0.04 to 0.15
Hz) and high frequency (HF - from 0.15 to 0.50 Hz) that represent the
sympathetic and vagal modulations, respectively<sup> [<xref rid="r11" ref-type="bibr">11</xref> ]</sup> . The spectral
components are reported as normalized units (LFun and HFun) and LF/HF ratio.
Normalization consisted of dividing the power of a given spectral component (HF
or LF) by the total power minus the power below 0.04 Hz, and multiplying the
ratio by 100.9 All patients presented a respiratory rate in the frequency range
of HF band of HRV.</p></sec><sec><title>Current medication intake</title><p>Medication profile is shown in <xref ref-type="table" rid="t01">Table 1</xref> .
Patients took angiotensin conversor enzyme inhibitors, losartan and isosorbide
5-mononitrate two times per day, one half of the daily dose in the morning (9:00
am) and the other half at night (9:00 pm). Diuretics were taken in the morning
(9:00 am). All heart transplant recipients were receiving immunosuppressive
therapy two times per day, one half of the daily dose in the morning and the
other half at night. Antihypertensive drugs were taken, most of the times, in
the morning.</p></sec><sec><title>Statistical analysis</title><p>Data are presented as mean and standard deviation. We evaluated the association
of the variables collected in the 60 selected patients. For this, we used
univariate analysis to select the variables to be used in the multivariate
model. For the univariate analysis, a significance level of less than 20%
(<italic>P</italic> &#x0003c;0.20) was considered. In multivariate analysis, the
nonsignificant variables were excluded from the model (manually, one at a time)
following the criterion of greater " <italic>P</italic> " value. The model was
determined when all the variables were presented with a significance level less
than 5% (<italic>P</italic> &#x0003c;0.05). The dependent variable used was the peak
VO<sub>2</sub>
<sup> [<xref rid="r01" ref-type="bibr">1</xref> ,<xref rid="r02" ref-type="bibr">2</xref> ,<xref rid="r05" ref-type="bibr">5</xref>
]</sup> . After the analysis, we established an equation with
variables associated with peak VO<sub>2</sub> .</p><p>For all statistical analyzes, we used SPSS (Chicago IL, USA) version 13.0.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Participants</title><p>From 176 heart transplant recipients alive in our service, 109 were not found by
phone calls or lived in another city that prevented the realization of the
protocol. Seven patients were excluded due to refusal, pacemaker or sequel of
stroke (<xref ref-type="fig" rid="f01">Figure 1</xref> ). Sixty patients (68%
male, 48 years and 64 months following heart transplantation) were assessed
(<xref ref-type="table" rid="t01">Table 1</xref> ).</p><fig id="f01" orientation="portrait" position="float"><label>Fig.1</label><caption><p>Patients flow throughout the study</p></caption><graphic xlink:href="rbccv-30-01-0009-g01"/></fig></sec><sec><title>Outcome data/main results</title><p>Univariate analysis selected the following variables: receptor's age
(<italic>P</italic> =0.042), receptor's BMI (<italic>P</italic> =0.056),
heart rate reserve (<italic>P</italic> &#x0003c;0.0001), percentage of age-predicted
peak heart rate (<italic>P</italic> =0.052), percentage of heart rate drop in
the second minute of recovery in the cardiopulmonary exercise test
(<italic>P</italic> =0.067), slope VE/VCO<sub>2</sub> (0.115), left atrium
diameter (<italic>P</italic> =0.028), right ventricular diameter
(<italic>P</italic> =0.079), E/E' ratio (0.144), cold ischemia time
(<italic>P</italic> =0.15), donor's age (<italic>P</italic> =0.022), LF/HF
(<italic>P</italic> =0.18) and receptor's sex (<italic>P</italic> =0.003).
The following variables were withdrawn from multivariate analysis model (in
order of withdrawal): slope VE/VCO<sub>2</sub> (<italic>P</italic> =0.957),
percentage of heart rate drop in the second minute of recovery in the
cardiopulmonary exercise test (<italic>P</italic> =0.937), percentage of
age-predicted peak heart rate (<italic>P</italic> =0.771), right ventricle
diameter (<italic>P</italic> =0.456), LF / HF (<italic>P</italic> =0.434),
donor's age (<italic>P</italic> =0.51), cold ischemia time (<italic>P</italic>
=0.227) and E/E' ratio (<italic>P</italic> =0.449).</p><p>Multivariate analysis selected the following variables: receptor's gender
(<italic>P</italic> =0.001), receptor age (<italic>P</italic> =0.049),
receptor BMI (<italic>P</italic> =0.005), heart rate reserve (<italic>P</italic>
&#x0003c;0.0001), left atrium diameter (<italic>P</italic> =0.016). Multivariate
analysis showed r=0.77 and r2=0.6 with<italic>P</italic> &#x0003c;0.001.</p><p>Equation derived from the multivariate analysis: peak VO<sub>2</sub> =32,851 -
receptor gender (3,708) - receptor age (0,067) - receptor BMI (0,318) + heart
rate reserve (0,145) - left atrium diameter (0,111)</p><p>Considering: peak VO<sub>2</sub> in mL/Kg/min, gender (0=male and 1=female), age
in years, BMI in Kg/m<sup>2</sup> , heart rate reserve in beats per minute and
left atrium diameter in millimeters.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The main finding of this study was that peak VO<sub>2</sub> of heart transplant
recipients was determined by receptor gender, age, BMI, heart rate reserve and left
atrium diameter.</p><p>Our study is the first one to investigate the determinants of peak VO<sub>2</sub> in
heart transplant recipients using variables that are non-invasive and easy to be
collected in clinical practice.</p><p>In our study, we observed that the peak VO<sub>2</sub> was negatively associated with
gender, BMI and age of the recipient and the diameter of the left atrium of the
allograft. Of these, gender and BMI seemed to be the determinants more strongly
associated with exercise capacity. Moreover, the heart rate reserve was the unique
variable positively associated to peak VO<sub>2</sub> .</p><p>Our data strongly suggest that the sympathetic reinnervation is the main variable
that positively influences peak VO<sub>2</sub> in heart transplant recipients.
Nevertheless, the parasympathetic reinnervation does not seem to influence the
exercise capacity in heart transplant recipients. Previous studies showed that the
parasympathetic reinnervation in adults is not consistent and may occur only from 5
to 10% of cases. Moreover, the sympathetic reinnervation occurs much more frequently
and is related to exercise capacity in heart transplant recipients from 50 to 60% of
cases in 3 years<sup> [<xref rid="r01" ref-type="bibr">1</xref> ,<xref rid="r12" ref-type="bibr">12</xref> ,<xref rid="r13" ref-type="bibr">13</xref> ]</sup> . The study by Bernardi et al.<sup> [<xref rid="r14" ref-type="bibr">14</xref> ]</sup> showed that exercise
training can improve cardiovascular control in heart transplant recipients.</p><p>The negative influence of BMI, age and gender in exercise capacity is already well
established in exercise physiology field. It is known that women have lower peak
VO<sub>2</sub> than men, as well as fatter people compared to skinny and older
people compared to younger, when we keep all other variables (such as exercise
training levels) constant<sup> [<xref rid="r15" ref-type="bibr">15</xref>
]</sup> .</p><p>A relatively new data appeared in our research: the negative influence of the left
atrium diameter in peak VO<sub>2</sub> in heart transplant recipients. The study by
Abdul-Waheed et al.<sup> [<xref rid="r16" ref-type="bibr">16</xref>
]</sup> showed that the left atrium of adult heart transplant recipients
increased in one year of follow-up. Moreover, this study showed an inverse
association between left atrium and peak VO<sub>2</sub> . The authors hypothesized
that the surgical scar could be negatively influencing left atrium pumping. In
agreement with Abdul-Waheed et al.<sup> [<xref rid="r16" ref-type="bibr">16</xref> ]</sup> , our study showed a similar relationship between
left atrium and exercise capacity. Unfortunately, our study can not explain the
mechanisms involved in this relationship, but the hypothesis raised by Abdul-Waheed
at al.<sup> [<xref rid="r16" ref-type="bibr">16</xref> ]</sup> seems
to be relevant and deserves a deep investigation in future studies.</p><p>The lack of influence of the time of transplant and the E/E' ratio in peak
VO<sub>2</sub> found in this study is an important information and deserves some
discussion. The E/E' ratio is an important echocardiography index in the diagnosis
of diastolic dysfunction and has been shown to be related to functional class,
cardiac mortality and hospitalization in patients with heart failure<sup>
[<xref rid="r17" ref-type="bibr">17</xref> ,<xref rid="r18" ref-type="bibr">18</xref> ]</sup> . The ratio above 15 is a strong
indicator of heart failure with preserved left ventricle ejection fraction. The E/E'
ratio between 8 and 15 represents a "gray zone" for diagnosis of diastolic
dysfunction. In these cases, B-type Natriuretic Peptide (BNP) seem to have a great
importance for the differential diagnosis<sup> [<xref rid="r19" ref-type="bibr">19</xref> ]</sup> .</p><p>The prevalence of diastolic dysfunction in our study was 3.4%, which we consider low
compared to 33% of the study by Roten et al.<sup> [<xref rid="r05" ref-type="bibr">5</xref> ]</sup> We expected that the prevalence of
diastolic dysfunction were higher and the E/E' ratio increased along the segment
after heart transplantation due to the increased incidence of co-morbidities such as
hypertension. There are no data in the literature regarding diastolic function (E/E'
ratio) and time of cardiac transplantation. We believe the fact that our patients
are well treated and compensated for comorbidities such as hypertension, the E/E'
ratio remained constant throughout the follow-up. In a curious way, our study showed
no association between peak VO<sub>2</sub> and the time of transplantation, but a
positive association between peak VO<sub>2</sub> and cardiac sympathetic
reinnervation through heart rate reserve. These data are quite relevant for a deeper
understanding of the behavior of exercise capacity over time of transplantation. It
seems that the real factor influencing exercise capacity is sympathetic
reinnervation and not simply the time of transplantation. This information let us
believe that for the same time following heart transplant, we will have more and
less reinnervated patients. Consequently we will have patients with higher and lower
exercise capacity.</p><p>Finally, the study by Roten et al.<sup> [<xref rid="r05" ref-type="bibr">5</xref> ]</sup> showed that the diastolic dysfunction was
associated with exercise capacity limitation of heart transplant recipients.
However, our study found no such association. Because of this conflicting data, some
considerations must be taken into account. In our study, the prevalence of diastolic
dysfunction was much lower than in the study by Roten et al.<sup> [<xref rid="r05" ref-type="bibr">5</xref> ]</sup> Perhaps if our study had
shown a higher prevalence of diastolic dysfunction (and consequent higher E/E'
ratio), our data would have agreed to the study by Roten et al.<sup> [<xref rid="r05" ref-type="bibr">5</xref> ]</sup> Therefore, further studies
in this area are necessary for a deeper understanding of the relationship between
peak VO<sub>2</sub> and the E/E' ratio.</p><p>This study has some limitations. Patients only performed resting echocardiography.
Certainly, the assessment of the cardiac function during exercise would bring
important information to the understanding of the relationship between E/E' ratio
and in exercise capacity of heart transplant recipients. In addition, further
investigation of the left atrium would be relevant for a better understanding of the
mechanisms involved in the limitation of exercise capacity.</p><p>This study was also limited by not assessing the vascular function and peripheral
muscle metabolism (oxygen extraction). Tests such as the kinetics of O<sub>2</sub> ,
would be useful in future research to evaluate the influence of the "periphery" in
the exercise capacity of transplanted patients.</p></sec><sec sec-type="conclusion"><title>CONCLUSION</title><p>In this study, the determinants of the peak VO<sub>2</sub> in heart transplant
recipients were: receptor gender, age, BMI, heart rate reserve and left atrium
diameter. Heart rate reserve was the unique variable that was positively associated
with peak VO<sub>2</sub> . This data suggest the importance of the sympathetic
reinnervation in peak VO<sub>2</sub> in heart transplant recipients.</p><table-wrap id="t03" orientation="portrait" position="float"><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="left" rowspan="1">Authors&#x02019; roles &#x00026;&#x000a0;responsibilities</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">VOC</td><td align="left" rowspan="1" colspan="1">Analysis and/or interpretation of data, statistical
analysis, final approval of the manuscript, conception and design of
the study, implementation of operations and/or experiments,
manuscript writing or critical review of its content</td></tr><tr><td align="left" rowspan="1" colspan="1">GVG</td><td align="left" rowspan="1" colspan="1">Analysis and/or interpretation of data, final approval
of the manuscript, design and study design, performance of
operations and/or experiments</td></tr><tr><td align="left" rowspan="1" colspan="1">MLCV</td><td align="left" rowspan="1" colspan="1">Analysis and/or interpretation of data, final approval
of the manuscript, current operations and/or experiments, manuscript
writing or critical review of its content</td></tr><tr><td align="left" rowspan="1" colspan="1">AMC</td><td align="left" rowspan="1" colspan="1">analysis and/or interpretation of data, final approval
of the manuscript, current operations and/or experiments, manuscript
writing or critical review of its content</td></tr><tr><td align="left" rowspan="1" colspan="1">VOC</td><td align="left" rowspan="1" colspan="1">Analysis and/or interpretation of data, final approval
of the manuscript, design and study design, performance of
operations and/or experiments, manuscript writing or critical review
of its content</td></tr><tr><td align="left" rowspan="1" colspan="1">SMAF</td><td align="left" rowspan="1" colspan="1">Analysis and/or interpretation of data, final approval
of the manuscript, current operations and/or experiments</td></tr><tr><td align="left" rowspan="1" colspan="1">EAB</td><td align="left" rowspan="1" colspan="1">Analysis and/or interpretation of data, final approval
of the manuscript, design and study design, performance of
operations and/or experiments, manuscript writing or critical review
of its content.</td></tr></tbody></table></table-wrap></sec></body><back><ref-list><title>REFERENCES</title><ref id="r01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bengel</surname><given-names>FM</given-names></name><name><surname>Ueberfuhr</surname><given-names>P</given-names></name><name><surname>Schiepel</surname><given-names>N</given-names></name><name><surname>Nekolla</surname><given-names>SG</given-names></name><name><surname>Reichart</surname><given-names>B</given-names></name><name><surname>Schwaiger</surname><given-names>M</given-names></name></person-group><article-title>Effect of sympathetic reinnervation on cardiac performance after
heart transplantation</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><issue>10</issue><fpage>731</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">11547742</pub-id></element-citation></ref><ref id="r02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>TC</given-names></name><name><surname>Ballman</surname><given-names>KV</given-names></name><name><surname>Allison</surname><given-names>TG</given-names></name><name><surname>Wagner</surname><given-names>JA</given-names></name><name><surname>Olson</surname><given-names>LJ</given-names></name><name><surname>Frantz</surname><given-names>RP</given-names></name><etal/></person-group><article-title>Clinical predictors of exercise capacity 1 year after cardiac
transplantation</article-title><source>J Heart Lung Transplant</source><year>2003</year><volume>22</volume><issue>1</issue><fpage>16</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">12531409</pub-id></element-citation></ref><ref id="r03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renlund</surname><given-names>DG</given-names></name><name><surname>Taylor</surname><given-names>DO</given-names></name><name><surname>Ensley</surname><given-names>RD</given-names></name><name><surname>O'Connell</surname><given-names>JB</given-names></name><name><surname>Gilbert</surname><given-names>EM</given-names></name><name><surname>Bristow</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Exercise capacity after heart transplantation: influence of donor
and recipient characteristics</article-title><source>J Heart Lung Transplant</source><year>1996</year><volume>15</volume><issue>1</issue><issue-part>Pt 1</issue-part><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">8820079</pub-id></element-citation></ref><ref id="r04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bengel</surname><given-names>FM</given-names></name><name><surname>Ueberfuhr</surname><given-names>P</given-names></name><name><surname>Schiepel</surname><given-names>N</given-names></name><name><surname>Nekolla</surname><given-names>SG</given-names></name><name><surname>Reichart</surname><given-names>B</given-names></name><name><surname>Schwaiger</surname><given-names>M</given-names></name></person-group><article-title>Effect of sympathetic reinnervation on cardiac performance after
heart transplantation</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><issue>10</issue><fpage>731</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">11547742</pub-id></element-citation></ref><ref id="r05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roten</surname><given-names>L</given-names></name><name><surname>Schmid</surname><given-names>JP</given-names></name><name><surname>Merz</surname><given-names>F</given-names></name><name><surname>Carrel</surname><given-names>T</given-names></name><name><surname>Zwahlen</surname><given-names>M</given-names></name><name><surname>Walpoth</surname><given-names>N</given-names></name><etal/></person-group><article-title>Diastolic dysfunction of the cardiac allograft and maximal
exercise capacity</article-title><source>J Heart Lung Transplant</source><year>2009</year><volume>28</volume><issue>5</issue><fpage>434</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">19416770</pub-id></element-citation></ref><ref id="r06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>JM</given-names></name><name><surname>Esch</surname><given-names>BT</given-names></name><name><surname>Haykowsky</surname><given-names>MJ</given-names></name><name><surname>Warburton</surname><given-names>DE</given-names></name><name><surname>Toma</surname><given-names>M</given-names></name><name><surname>Jelani</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cardiovascular responses to incremental and sustained submaximal
exercise in heart transplant recipients</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2009</year><volume>296</volume><issue>2</issue><fpage>H350</fpage><lpage>H358</lpage><pub-id pub-id-type="pmid">19060120</pub-id></element-citation></ref><ref id="r07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>RM</given-names></name><name><surname>Badano</surname><given-names>LP</given-names></name><name><surname>Tsang</surname><given-names>W</given-names></name><name><surname>Adams</surname><given-names>DH</given-names></name><name><surname>Agricola</surname><given-names>E</given-names></name><name><surname>Buck</surname><given-names>T</given-names></name><etal/><collab>American Society of EchocardiographyEuropean Association of
Echocardiography</collab></person-group><article-title>EAE/ASE recommendations for image acquisition and display using
three-dimensional echocardiography</article-title><source>Eur Heart J Cardiovasc Imaging</source><year>2012</year><volume>13</volume><issue>1</issue><fpage>1</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">22275509</pub-id></element-citation></ref><ref id="r08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loimaala</surname><given-names>A</given-names></name><name><surname>Siev&#x000e4;nen</surname><given-names>H</given-names></name><name><surname>Laukkanen</surname><given-names>R</given-names></name><name><surname>P&#x000e4;rkk&#x000e4;</surname><given-names>J</given-names></name><name><surname>Vuori</surname><given-names>I</given-names></name><name><surname>Huikuri</surname><given-names>H</given-names></name></person-group><article-title>Accuracy of a novel real-time microprocessor QRS detector for
heart rate variability assessment</article-title><source>Clin Physiol</source><year>1999</year><volume>19</volume><issue>1</issue><fpage>84</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">10068870</pub-id></element-citation></ref><ref id="r09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malliani</surname><given-names>A</given-names></name><name><surname>Pagani</surname><given-names>M</given-names></name><name><surname>Lombardi</surname><given-names>F</given-names></name><name><surname>Cerutti</surname><given-names>S</given-names></name></person-group><article-title>Cardiovascular neural regulation explored in the frequency
domain</article-title><source>Circulation</source><year>1991</year><volume>84</volume><issue>2</issue><fpage>482</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">1860193</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagani</surname><given-names>M</given-names></name><name><surname>Lombardi</surname><given-names>F</given-names></name><name><surname>Guzzetti</surname><given-names>S</given-names></name><name><surname>Rimoldi</surname><given-names>O</given-names></name><name><surname>Furlan</surname><given-names>R</given-names></name><name><surname>Pizzinelli</surname><given-names>P</given-names></name><etal/></person-group><article-title>Power spectral analysis of heart rate and arterial pressure
variabilities as a marker of sympatho-vagal interaction in man and conscious
dog</article-title><source>Circulation Res</source><year>1986</year><volume>59</volume><issue>2</issue><fpage>178</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">2874900</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Task Force of the European Society of Cardiology and the North
American Society of Pacing and Electrophysiology</collab></person-group><article-title>Heart rate variability: standards of measurement, physiological
interpretation and clinical use</article-title><source>Circulation</source><year>1996</year><volume>93</volume><issue>5</issue><fpage>1043</fpage><lpage>1065</lpage><pub-id pub-id-type="pmid">8598068</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramaekers</surname><given-names>D</given-names></name><name><surname>Ector</surname><given-names>H</given-names></name><name><surname>Vanhaecke</surname><given-names>J</given-names></name><name><surname>van Cleemput</surname><given-names>J</given-names></name><name><surname>van de Werf</surname><given-names>F</given-names></name></person-group><article-title>Heart rate variability after cardiac transplantation in
humans</article-title><source>Pacing Clin Electrophysiol</source><year>1996</year><volume>19</volume><issue>12</issue><issue-part>Pt 1</issue-part><fpage>2112</fpage><lpage>2119</lpage><pub-id pub-id-type="pmid">8994951</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>RF</given-names></name><name><surname>Laxson</surname><given-names>DD</given-names></name><name><surname>Christensen</surname><given-names>BV</given-names></name><name><surname>McGinn</surname><given-names>AL</given-names></name><name><surname>Kubo</surname><given-names>SH</given-names></name></person-group><article-title>Regional differences in sympathetic reinnervation after human
orthotopic cardiac transplantation</article-title><source>Circulation</source><year>1993</year><volume>88</volume><issue>1</issue><fpage>165</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">8319329</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernardi</surname><given-names>L</given-names></name><name><surname>Radaelli</surname><given-names>A</given-names></name><name><surname>Passino</surname><given-names>C</given-names></name><name><surname>Falcone</surname><given-names>C</given-names></name><name><surname>Auguadro</surname><given-names>C</given-names></name><name><surname>Martinelli</surname><given-names>L</given-names></name><etal/></person-group><article-title>Effects of physical training on cardiovascular control after
heart transplantation</article-title><source>Int J Cardiol</source><year>2007</year><volume>118</volume><issue>3</issue><fpage>356</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">17050012</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>GF</given-names></name><name><surname>Balady</surname><given-names>GJ</given-names></name><name><surname>Amsterdam</surname><given-names>EA</given-names></name><name><surname>Chaitman</surname><given-names>B</given-names></name><name><surname>Eckel</surname><given-names>R</given-names></name><name><surname>Fleg</surname><given-names>J</given-names></name><etal/></person-group><article-title>Exercise standards for testing and training: a statement for
healthcare professionals from the American Heart Association</article-title><source>Circulation</source><year>2001</year><volume>104</volume><issue>14</issue><fpage>1694</fpage><lpage>1740</lpage><pub-id pub-id-type="pmid">11581152</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdul-Waheed</surname><given-names>M</given-names></name><name><surname>Yousuf</surname><given-names>M</given-names></name><name><surname>Kelly</surname><given-names>SJ</given-names></name><name><surname>Arena</surname><given-names>R</given-names></name><name><surname>Ying</surname><given-names>J</given-names></name><name><surname>Naz</surname><given-names>T</given-names></name><etal/></person-group><article-title>Does left atrial volume affect exercise capacity of heart
transplant recipients?</article-title><source>J Cardiothorac Surg</source><year>2010</year><volume>5</volume><fpage>113</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">21083921</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamdan</surname><given-names>A</given-names></name><name><surname>Shapira</surname><given-names>Y</given-names></name><name><surname>Bengal</surname><given-names>T</given-names></name><name><surname>Mansur</surname><given-names>M</given-names></name><name><surname>Vaturi</surname><given-names>M</given-names></name><name><surname>Sulkes</surname><given-names>J</given-names></name><etal/></person-group><article-title>Tissue Doppler imaging in patients with advanced heart failure:
relation to functional class and prognosis</article-title><source>J Heart Lung Transplant</source><year>2006</year><volume>25</volume><issue>2</issue><fpage>214</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">16446223</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galrinho</surname><given-names>A</given-names></name><name><surname>Branco</surname><given-names>L</given-names></name><name><surname>Soares</surname><given-names>R</given-names></name><name><surname>Tim&#x000f3;teo</surname><given-names>A</given-names></name><name><surname>Abreu</surname><given-names>J</given-names></name><name><surname>Leal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prognostic implications of tissue Doppler in patients with
dilated cardiomyopathy</article-title><source>Rev Port Cardiol</source><year>2006</year><volume>25</volume><issue>9</issue><fpage>781</fpage><lpage>793</lpage><pub-id pub-id-type="pmid">17100169</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bocchi</surname><given-names>EA</given-names></name><name><surname>Braga</surname><given-names>FG</given-names></name><name><surname>Ferreira</surname><given-names>SM</given-names></name><name><surname>Rohde</surname><given-names>LE</given-names></name><name><surname>Oliveira</surname><given-names>WA</given-names></name><name><surname>Almeida</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Sociedade Brasileira de Cardiologia. III Brazilian Guidelines on
Chronic Heart Failure</article-title><source>Arq Bras Cardiol</source><year>2009</year><volume>93</volume><issue>1</issue><supplement>Suppl 1</supplement><fpage>3</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">20963312</pub-id></element-citation></ref></ref-list></back></article>